FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171567454> ?p ?o ?g. }

• W2171567454 endingPage "i12" @default.
• W2171567454 startingPage "i6" @default.
• W2171567454 abstract "Since the middle of the 20th century, particle therapy has been in focus for patient treatments. In 1946, Robert Wilson proposed the use of charged particles for tumor therapy, and since then, the clinical use of protons and heavier ions, mainly carbon ions, has become more widespread [1]. The first clinical evidence was obtained in Berkeley, treating radiation-resistant targets with various ion species [2–14]. The main advantage of particle beams derive from their physical properties: through an inverted dose profile, regions within the entry channel of the beam can be spared of dose, while a steep dose deposition can be directed in an energy-dependent manner into the defined treatment volume (Bragg Peak). The following dose fall-off spares tissue behind the target volume, thus reducing integral dose significantly compared to when using photons. Heavier charged particles, such as carbon ions or oxygen, are additionally associated with an increased relative biological effectiveness (RBE), while the RBE of protons is commonly accepted to be about 1.1 [15, 16]. Recent observation, however, suggests that this may be an oversimplification.Carbon ion radiotherapy is currently available in only a few centers worldwide: mainly in Japan, with two centers in Europe (CNAO, Pavia, Italy and HIT, Heidelberg, Germany). For proton therapy, treating centers are more widespread throughout the USA and Asia, with a few centers in Europe. Most clinical data has been reported as smaller series within Phase I/II trials, or retrospectively assembled data from patient subgroups, most indications being sarcomas, malignant salivary gland tumors or ocular melanoma [2, 17–22]. The only large randomized trial comparing protons to photons was performed in patients with prostate cancer, where proton therapy was applied as a boost in the experimental arm to a higher total dose than in the control arm [23, 24]; this trial did show a benefit in terms of biochemical progression-free survival, with overall comparable toxicity [25]. Over the years, photon treatments have improved and modern intensity-modulated radiotherapy (IMRT) and image-guided radiotherapy (IGRT) approaches enable the radiation oncologist to deliver doses of ∼80 Gy to the prostate safely. This is not the dose concept and technical background that was implemented in that trial. Therefore, controversy remains about the real value of this trial, i.e. comparing ‘protons vs photons’, or comparing ‘high dose vs low dose’.Currently, the cost of particle therapy is a multiple of that of photon treatments, due to the size of structures, the complexity of technology required, the resulting investment and also the high running cost; additionally, capacity for treatment is still limited [18, 26, 27]. Therefore, current discussions focus on the indications for particle therapy.Therefore, besides seeking technical improvement and developments to make particle therapy less costly and more widely available, four main clinical foci are of importance: design of clinical trials comparing protons, carbon ions and advanced photon techniques for selected tumor indications;identification of prognostic markers, i.e. molecular characteristics, imaging properties or normal tissue qualities stratifying patients;better understanding of patient- and tumor-specific RBE for protons and heavier ions alike;integration of particles into multimodal treatment with systemic approaches together with surgery.Integrating such novel tools into modern radiation oncology requires large-scale preclinical and clinical research in the fields of biology, physics and medicine. To bring together the expertise of various researchers of all stages, and to educate newcomers into the field through dissemination of knowledge, joint European structures were generated as a platform to incorporate protons and heavier ions into modern radiation oncology concepts." @default.
• W2171567454 created "2016-06-24" @default.
• W2171567454 creator A5000377815 @default.
• W2171567454 creator A5019777534 @default.
• W2171567454 creator A5023618347 @default.
• W2171567454 creator A5034385198 @default.
• W2171567454 creator A5039829347 @default.
• W2171567454 creator A5061037633 @default.
• W2171567454 creator A5062450662 @default.
• W2171567454 creator A5071564915 @default.
• W2171567454 creator A5074069308 @default.
• W2171567454 creator A5079460128 @default.
• W2171567454 creator A5083101824 @default.
• W2171567454 creator A5083672016 @default.
• W2171567454 date "2013-07-01" @default.
• W2171567454 modified "2023-09-27" @default.
• W2171567454 title "Towards clinical evidence in particle therapy: ENLIGHT, PARTNER, ULICE and beyond" @default.
• W2171567454 cites W140385798 @default.
• W2171567454 cites W1515726259 @default.
• W2171567454 cites W1970390633 @default.
• W2171567454 cites W1989329231 @default.
• W2171567454 cites W1989983799 @default.
• W2171567454 cites W1992063976 @default.
• W2171567454 cites W1996809772 @default.
• W2171567454 cites W1999665755 @default.
• W2171567454 cites W2016490373 @default.
• W2171567454 cites W2022973126 @default.
• W2171567454 cites W2052281868 @default.
• W2171567454 cites W2052684306 @default.
• W2171567454 cites W2053700561 @default.
• W2171567454 cites W2055865610 @default.
• W2171567454 cites W2058640590 @default.
• W2171567454 cites W2064105580 @default.
• W2171567454 cites W2067472600 @default.
• W2171567454 cites W2071756413 @default.
• W2171567454 cites W2072379125 @default.
• W2171567454 cites W2083533187 @default.
• W2171567454 cites W2086693993 @default.
• W2171567454 cites W2088413560 @default.
• W2171567454 cites W2091780056 @default.
• W2171567454 cites W2098443648 @default.
• W2171567454 cites W2098733695 @default.
• W2171567454 cites W2112937739 @default.
• W2171567454 cites W2132253804 @default.
• W2171567454 cites W2134766048 @default.
• W2171567454 cites W2135396619 @default.
• W2171567454 cites W2137568839 @default.
• W2171567454 cites W2151400824 @default.
• W2171567454 cites W2161252920 @default.
• W2171567454 cites W2165813281 @default.
• W2171567454 cites W2166098780 @default.
• W2171567454 cites W2168261092 @default.
• W2171567454 cites W2172085424 @default.
• W2171567454 cites W3205645758 @default.
• W2171567454 cites W381194250 @default.
• W2171567454 doi "https://doi.org/10.1093/jrr/rrt039" @default.
• W2171567454 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3700508" @default.
• W2171567454 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23824128" @default.
• W2171567454 hasPublicationYear "2013" @default.
• W2171567454 type Work @default.
• W2171567454 sameAs 2171567454 @default.
• W2171567454 citedByCount "12" @default.
• W2171567454 countsByYear W21715674542014 @default.
• W2171567454 countsByYear W21715674542015 @default.
• W2171567454 countsByYear W21715674542016 @default.
• W2171567454 countsByYear W21715674542018 @default.
• W2171567454 countsByYear W21715674542019 @default.
• W2171567454 crossrefType "journal-article" @default.
• W2171567454 hasAuthorship W2171567454A5000377815 @default.
• W2171567454 hasAuthorship W2171567454A5019777534 @default.
• W2171567454 hasAuthorship W2171567454A5023618347 @default.
• W2171567454 hasAuthorship W2171567454A5034385198 @default.
• W2171567454 hasAuthorship W2171567454A5039829347 @default.
• W2171567454 hasAuthorship W2171567454A5061037633 @default.
• W2171567454 hasAuthorship W2171567454A5062450662 @default.
• W2171567454 hasAuthorship W2171567454A5071564915 @default.
• W2171567454 hasAuthorship W2171567454A5074069308 @default.
• W2171567454 hasAuthorship W2171567454A5079460128 @default.
• W2171567454 hasAuthorship W2171567454A5083101824 @default.
• W2171567454 hasAuthorship W2171567454A5083672016 @default.
• W2171567454 hasBestOaLocation W21715674541 @default.
• W2171567454 hasConcept C126322002 @default.
• W2171567454 hasConcept C15744967 @default.
• W2171567454 hasConcept C2778418280 @default.
• W2171567454 hasConcept C509974204 @default.
• W2171567454 hasConcept C542102704 @default.
• W2171567454 hasConcept C71924100 @default.
• W2171567454 hasConceptScore W2171567454C126322002 @default.
• W2171567454 hasConceptScore W2171567454C15744967 @default.
• W2171567454 hasConceptScore W2171567454C2778418280 @default.
• W2171567454 hasConceptScore W2171567454C509974204 @default.
• W2171567454 hasConceptScore W2171567454C542102704 @default.
• W2171567454 hasConceptScore W2171567454C71924100 @default.
• W2171567454 hasIssue "suppl 1" @default.
• W2171567454 hasLocation W21715674541 @default.
• W2171567454 hasLocation W21715674542 @default.
• W2171567454 hasLocation W21715674543 @default.
• W2171567454 hasLocation W21715674544 @default.

• next